French mathematician Professor Jean-Pierre Bourguignon has taken over as president of the European Research Council (ERC), the first pan-European funding organisation for frontier research.
The appointment coincides with the start of the EU’s biggest ever research funding programme, Horizon 2020, worth nearly EUR 80 billion over the next seven years. The ERC’s budget has been increased to over EUR 13 billion under the new programme.
Prof. Jean-Pierre Bourguignon will be the first ERC president to be based in Brussels in a reinforced role that will enable him to ensure closer cooperation with the European Commission, and monitor the implementation of the ERC Scientific Council’s strategy.
‘Professor Bourguignon is the right choice for this task, given his distinguished academic career, international renown, and proven record of leadership.’
Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science
‘Professor Bourguignon is the right choice for this task, given his distinguished academic career, international renown, and proven record of leadership,’ said Research, Innovation and Science Commissioner, Máire Geoghegan-Quinn. ‘I am confident that he will defend the ERC principles of excellence and independence.’
He is the third president of the ERC since its launch in 2007, and succeeds Austrian social scientist Professor Helga Nowotny, who headed the organisation from 2010 to 2013.
Prof. Bourguignon, who took over at the start of the year, was the first chairman of the ERC’s mathematics peer review panel. As the ERC president, he has been given a four-year mandate, which is renewable once.
Discussing his new role in an interview posted on the ERC’s website, Prof. Bourguignon said: ‘I measure the responsibility ... in particular because of the fantastic success that the ERC has been in such a short period of time.’
Prof. Bourguignon was the Director of the Institut des Hautes Études Scientifiques (IHÉS) from 1994 till 2013. This international research institute located near Paris, France, was built as the European counterpart of the Institute for Advanced Study in Princeton, US.
He is a fellow of the French National Centre for Scientific Research (CNRS). He has received several awards for his research from the French Academy of Sciences in Paris. He is also a foreign member of the Spanish Royal Academy of Sciences, and has been made Doctor Honoris Causa of Keio University, Japan, and Nankai University, China.
The interview with the new president of the ERC, Professor Jean-Pierre Bourguignon:
Preserving biodiversity is one of the key debates of our time – but another subject of hot debate in recent decades among evolutionary experts is how biodiversity has changed over the past few hundred million years. New findings are challenging the conventional view on this.
Transfusing antibodies from Covid-19 survivors into seriously ill patients could provide a quick treatment win, but a more selective approach may both treat and prevent the disease. A single, highly-effective antibody that is mass-produced like a drug could combine the benefits of antivirals and a vaccine for at-risk individuals such as health workers.
The iridescence of marble berries and the clever, light-bending perforations of microalgae are some lessons from nature that scientists are drawing upon to create biodegradable glitter and makeup pigments, and bionic algae to use in lasers or to clean pollutants.
Efforts to design a safe vaccine for Covid-19 are moving forward at full throttle, yet experts agree that it’s likely to be a year, at least, before an immunisation is ready. Meanwhile, scientists around Europe are exploring ingenious ways – including with the help of alpacas – to use the latest techniques in molecular manipulation to repair coronavirus-induced lung damage or to block the virus before it wreaks havoc.
Scientists are drawing on nature’s clever ways to build structures and produce iridescence.
Infection-halting therapies being explored include neutralising antibodies.
Metagenomics can help us spot emerging diseases such as coronavirus, says virologist Marion Koopmans.